


**PRINTER
FRIENDLY!**

Pharmacology Update: *Integrating Advances Into Practice E-Conference*

Friday, June 27 • 9 am–6:15 pm EST



Use the notes area throughout the guide to capture what you learn at each session.

Education or Content-Related Questions

ONS Customer Service
866-257-4ONS (phone)
412-859-6120
econference@ons.org

Please note that the conference schedule follows Eastern Standard Time.

Technical Support Questions

Blue Sky Broadcast
7 am–6:15 pm EST
877-925-8375, option 1 (phone)
support@blueskybroadcast.com

Attendee GUIDE

www.ons.org/pharmacology2014



Pharmacology Update:

Integrating Advances Into Practice E-Conference

WELCOME ATTENDEES

Get ready to watch nationally renowned experts present live on your computer. Through the easy-to-use virtual experience platform, you'll be able to ask questions, interact with other attendees, and visit the e-posters without ever leaving your home or office. You can download the slides and other handouts and resources so that you have them at your fingertips.

PROGRAM GOAL

The goal of this e-conference is to get an overview of recently FDA-approved pharmacologic agents and recently expanded indications for pharmacologic agents in cancer care.

TARGET AUDIENCE

This program is intended for advanced practice oncology nurses, prescribers, clinicians, or any healthcare professionals who desire to increase their knowledge related to pharmacology in cancer care.

At the end of this e-conference, participants will be able to

- Discuss the indications and nursing considerations associated with newly approved pharmacologic agents.
- Describe the process for evaluation and review of literature for drug therapy in cancer care.
- Given a patient case, discuss the clinical care considerations for short- and long-term management of endocrine therapy for the individual with breast cancer.
- Given a patient case, discuss the clinical care considerations for short- and long-term management of endocrine therapy for the individual with prostate cancer.
- Outline the immune-related adverse reactions associated with cancer treatment, and discuss monitoring, prevention, and management of those effects.
- Describe three highlights from abstracts presented at the American Society of Clinical Oncology's 2014 annual meeting, and discuss the potential impact on cancer care in the future.
- Discuss how precision cancer treatment is becoming increasingly personalized, and identify the implications for patient care.

**ONS would like to thank the following
educational grant supporters:**

AstraZeneca LP

Astellas Pharma US, Inc., in collaboration with Medivation.

Schedule at a Glance

Friday, June 27

9–10 am EST

American Society of Clinical
Oncology Meeting Highlights

10:15–11:15 am EST

Personalized Medicine

11:30 am–12:30 pm EST

Strategies to Optimize
Interpretation of the Oncology
Literature

12:30–1:30 pm EST

Break: E-Poster Presentations
and Showcase

1:30–2:30 pm EST

Hormonal Manipulation: Breast

2:45–3:45 pm EST

Hormonal Manipulation:
Prostate

4–5 pm EST

Immune-Related Adverse
Effects

5:15–6:15 pm EST

New Drug Update

Time Zone Conversions

- 9 am–6:15 pm EST
- 8 am–5:15 pm CT
- 7 am–4:15 pm MT
- 6 am–3:15 pm PT

**Please note that the conference
schedule follows Eastern Standard
Time.*

Please note that this e-conference will not be archived or made available for purchase after the live event.

To ensure an optimal experience, use one of the following supported browsers on your desktop or laptop computer. Please also refer to the system requirements located on the e-conference portal.

Supported Browsers for Desktop or Laptop Computers

Firefox 3+
Internet Explorer 9+
Safari 3.1+
Google Chrome

Additional Requirements

Javascript enabled
Flash 9+
Cookies enabled
Access to YouTube

Obtaining Continuing Education Credit

CONTINUING NURSING EDUCATION

Attendees of the Pharmacology Update: Integrating Advances Into Practice E-Conference **can earn 8 contact hours of continuing nursing education.** Participants must attend sessions in their entirety and **submit a completed evaluation by Monday, July 28, 2014, to receive CNE credit.**

ONS is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC's) Commission on Accreditation. **To obtain CNE credit for this activity, visit <http://myoutcomes.ons.org>. Login using your ONS profile username and password.** Complete and submit the evaluation for each session attended, then evaluate the overall conference. Your CNE certificate will be available under Transcripts.

ONS is approved as a provider of continuing education by the California Board of Registered Nursing, Provider #2850.

Accreditation as an ANCC Commission provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

The contact hours earned from this educational opportunity qualify for initial oncology nursing certification and renewal via ONC-PRO and ILNA. Visit www.oncc.org for complete details on oncology nursing certification.



CONTINUING PHARMACY EDUCATION

How to Claim CPE Credit

CPE credit is available for the Hormonal Manipulation Prostate and New Drug Update 2013/2014 sessions.

- Hormonal Manipulation Prostate (ACPE #0202-0000-14-112-L04-P) is a knowledge-based activity approved for 1.0 contact hour or 0.10 CEUs of continuing pharmacy education credit.
- New Cancer Drug Update 2013/2014 (ACPE #0202-0000-14-113-L04-P) is a knowledge-based activity approved for 1.0 contact hour or 0.10 CEUs of continuing pharmacy education credit.

To obtain CPE credit for this activity, you are required to actively participate in the activity and complete an evaluation. The attendance code is needed to access and complete the evaluation. **To complete the evaluation, participants will need to have a valid Pharmacist.com username and password.**

- Log in with your Pharmacist.com username and a password or create one as directed. You will need a valid NABP e-profile ID number from cpemonitor.net to claim credit.
- Select "Claim Credit" next to ONS E-Conference Pharmacology Update: Integrating Advances Into Practice.
- Enter the attendance code(s) given during the session.
- Follow the on-screen instructions to complete the activity evaluation.
- **You must claim your credit by Monday, July 28.**
- Your transcript of CPE credit can be found at cpemonitor.net.



The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Personalized Medicine

*Kristine Abueg, RN, MSN, OCN®, CBCN®
Clinical Research Nurse
Kaiser Permanente
Roseville, CA*

Full disclosure: Nothing to disclose.

Treatment planning is becoming more refined, evolving from treatment of categories of similar patients to treatment of a patient’s singular unique profile. By using case studies, patient biopsychosocial factors, histology, tumor staging, and molecular/genetic biomarkers will be discussed.

At the end of this presentation, you’ll be able to

1. Explain the impact of histology, biomarkers, tumor staging, and biopsychosocial patient factors on personalized medicine treatment planning.
2. Analyze patient-specific biomarker alterations with respect to prognosis and drug selection.

Notes: _____

Strategies to Optimize Interpretation of the Oncology Literature

Rowena Schwartz, PharmD
Senior Director, Clinical Content and Services
McKesson Specialty Health
The Woodlands, TX

Full disclosure: Nothing to disclose.

The advent of evidence-based medicine has required that clinical practitioners are able to access and evaluate information from the medical literature, and ultimately apply the evidence to patient care. The discussion will include strategies to optimize the search for literature, approaches to critically appraise information and/or literature that is available, and considerations when applying information from the literature to patient care.

At the end of this presentation, you'll be able to

1. Describe the potential versus real concern regarding influence of financial relationship or sponsorship on authors of paper.
2. When given a published article on a clinical trial, evaluate the limitation of the study population for broad application in clinical practice.
3. Discuss the risks and benefits of using a surrogate end point in a clinical trial.
4. Outline the factors to consider when evaluating a treatment recommendation in the medical literature.
5. Discuss the benefits and risks of subgroup analysis of a clinical trial.

Notes: _____

E-Poster Presentations and Showcase

E-Poster #200 - Differences in Metabolite Activity of the Selective Estrogen-Receptor Modulators Tamoxifen and Toremifene: Clinical Implications for Patients With Hormone Receptor-Positive Breast Cancer

–Presented by Carolyn Lavender, MSN, AOCNP®, ARNP, ProStrakan, Bridgewater, NJ

E-Poster #300 - Efficacy of a Transdermal Granisetron Patch in Controlling Chemotherapy-Induced Nausea and Vomiting in Head and Neck Cancer Patients

–Presented by Carolyn Lavender, MSN, AOCNP®, ARNP, ProStrakan, Bridgewater, NJ

E-Poster Presentations and Showcase

E-Poster #400 - Adjuvant Treatment With Toremifene in Hormone Receptor–Positive Breast Cancer: A Systematic Review of the Literature

–Presented by *Deborah Braccia, PhD, MPA, RN, ProStrakan, Bridgewater, NJ*

E-Poster #500 - Decreasing Fall Risk With Attention to Chemotherapy Premedications

–Presented by *Ashley Mickiewicz, BSN, RN, OCN®, Robert Wood Johnson University Hospital, New Brunswick, NJ*

Hormonal Manipulation: Breast

*Laura Michaud, PharmD, BCOP, FASHP
Manager, Clinical Pharmacy Services
MD Anderson Cancer Center
Houston, TX*

Full disclosure: Nothing to disclose.

This session will explain the incidence of breast cancer, focusing on hormone-receptor breast cancer, survival, and use of endocrine therapy alone and in combination with biologic, targeted therapies in early-stage and metastatic breast cancer. It will also review long-term adverse effects associated with selective estrogen-receptor modulators, aromatase inhibitors, everolimus, and anti-HER2 agents. Case studies will round out the discussion to include appropriate monitoring plans for patients on these medications.

At the end of this presentation, you'll be able to

1. Explain the incidence and management of long-term adverse events associated with endocrine therapy when administered to patients with breast cancer.
2. Summarize appropriate monitoring plans for surveillance in patients receiving endocrine therapy for breast cancer.

Notes: _____

New Drug Update*

*Teresa Knoop, MSN, RN, AOCN®
Assistant Director, Clinical Trials Shared Resource
Vanderbilt-Ingram Comprehensive Cancer Center
Nashville, TN*

Full disclosure: Nothing to disclose.

Gain an introduction to newly FDA-approved cancer treatments, while obtaining helpful tips to quickly grasp drug classifications. This discussion will also include multidisciplinary trends in drug development, discussion of the newly approved molecular agents, and a look at future directions for cancer therapies.

At the end of this presentation, you'll be able to

1. Identify new drugs that have been FDA-approved for cancer treatment in 2014.
2. Describe how new drugs are given generic names and how to gain information about new drugs based on the generic naming system.

Notes: _____

*See page 4 for information on how to earn CPE for this session.

